Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis Publication Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis This article describes how a model-informed drug development (MIDD) approach was used to support the…Certara2026 年 3 月 24 日
Regulatory horizons 2026: Clinical pharmacology strategy and regulatory expectations Blog Regulatory horizons 2026: Clinical pharmacology strategy and regulatory expectations Learn how regulatory expectations in clinical pharmacology are evolving and how to build a strategy…Certara2026 年 3 月 24 日
From Numbers to Narrative: Mastering the Art of PK Presentation Guide From Numbers to Narrative: Mastering the Art of PK Presentation Master PK data reporting with a structured guide to presenting pharmacokinetic results clearly and turning…Certara2026 年 3 月 20 日
Pediatric Drug Development and Pharmacometrics: Key Questions Sponsors Must Answer Guide Pediatric Drug Development and Pharmacometrics: Key Questions Sponsors Must Answer Download Certara’s expert guide on pharmacometrics and pediatric drug development. Learn how modeling, MIDD, and…Certara2026 年 3 月 19 日
Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026 Blog 通过模型引导的药物开发促进药物公平:ASCPT 2026 见解 Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…Certara2026 年 3 月 11 日
Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers Webinar Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers Certara2026 年 3 月 9 日
Navigate GxP Compliance in the Cloud with Confidence Guide Navigate GxP Compliance in the Cloud with Confidence Master SaaS GxP compliance with risk-based computer system validation (CSV) aligned to GAMP 5, FDA,…Certara2026 年 3 月 6 日
ADC first-in-human (FIH) dose selection: Designing FIH studies for success Blog ADC 首次人体(FIH)剂量选择:成功设计 FIH 研究的关键 Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…Certara2026 年 3 月 3 日
Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development Conference Apotekarsocieteten 临床药理学策略在药物开发中的应用 Danielle Pillsbury2026 年 3 月 2 日